查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1611289

罕見疾病診斷市場：按組成部分、技術、疾病類型和最終用途 - 2025-2030 年全球預測

Rare Disease Diagnostics Market by Component (Consumable & Assay Kit, Diagnostic Instrument), Technology (Array Technology, Next Generation Sequencing, Sanger Sequencing), Disease Type, End-use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年，罕見疾病診斷市場價值為26.8億美元，預計到2024年將達到31.2億美元，複合年成長率為17.36%，預計到2030年將達到82.3億美元。

罕見疾病診斷市場的特點是它在識別和管理影響一小部分人口的疾病方面發揮著重要作用。該細分市場需要先進的創新來提高診斷過程的準確性和及時性。早期療育和個人化治療計劃的潛力凸顯了對增強診斷的需求，這些計劃可以顯著改善患者的治療結果。應用包括基因檢測、生物標記檢測和先進的診斷影像技術，最終用途包括醫院、診斷實驗室和研究機構。推動該市場成長的關鍵因素包括人們對罕見疾病的認知不斷提高、基因組學和生物技術的進步以及政府的支持措施和資金。此外，向個人化醫療的轉變正在發揮關鍵作用，人工智慧和機器學習的整合也能提高診斷準確性和決策能力。

主要市場統計
基準年[2023] 26.8億美元
預計年份 [2024] 31.2億美元
預測年份 [2030] 82.3億美元
複合年成長率（%） 17.36%

目前的市場開拓機會在於攜帶式診斷工具的開發和新興經濟體的市場擴張，這些市場仍有大量未滿足的需求。生物技術公司、政府機構和醫療保健提供者之間的策略夥伴關係有助於加速技術的採用。然而，挑戰依然存在，包括先進診斷的高成本、監管障礙以及缺乏訓練有素的專業人員。市場開拓也受到罕見疾病的異質性和複雜性的限制，這使得標準化診斷通訊協定的發展變得複雜。創新前景包括加強基因檢測平台、開發多組體學方法以及利用巨量資料更深入了解疾病機制。

市場本質上是動態的，培養競爭格局需要持續研究、對監管變化做出敏捷響應以及對人才發展的投資。該領域的參與企業必須注重學術界、高科技和醫療產業之間的合作，以促進創新並提高診斷準確性。總體而言，罕見疾病診斷市場對於那些希望克服其複雜性同時改善患者照護的公司來說具有巨大的潛力。

市場動態：揭示快速發展的罕見疾病診斷市場的關鍵市場洞察

供需的動態交互作用正在改變罕見疾病診斷市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 罕見遺傳病患疾病率不斷上升，需要早期快速診斷
    • 擴大使用翻譯和基因組研究來識別新突變
    • 政府在罕見疾病診斷和治療方面的舉措
  • 市場限制因素
    • 與新的罕見疾病基因檢測核准程序相關的嚴格規定
  • 市場機會
    • 基因技術的進步識別新的罕見疾病基因
    • 罕見遺傳疾病診斷的獲利投資
  • 市場問題
    • 道德問題和罕見疾病資訊的獲取有限

波特五力：駕馭罕見疾病診斷市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解罕見疾病診斷市場的外部影響

外部宏觀環境因素在塑造罕見疾病診斷市場的表現動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析：了解罕見疾病診斷市場的競爭狀況

對罕見疾病診斷市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：罕見疾病診斷市場供應商績效評估

FPNV定位矩陣是評估罕見疾病診斷市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製罕見疾病診斷市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，罕見疾病診斷市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1.市場滲透率：對當前市場環境的詳細審查，主要企業的廣泛資料，評估他們在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、主要產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 罕見遺傳疾病的增加以及早期快速診斷的需求
      • 擴大使用轉化研究和基因組監測來識別新突變
      • 政府關於罕見疾病診斷和治療的舉措
    • 抑制因素
      • 新罕見疾病基因檢測核准流程的嚴格規定
    • 機會
      • 基因技術的進步識別新的罕見疾病基因
      • 罕見遺傳疾病診斷的獲利投資
    • 任務
      • 道德問題和罕見疾病資訊的獲取有限
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章 罕見疾病診斷市場：依組成部分

  • 介紹
  • 耗材和檢測試劑套件
  • 診斷設備

第7章 罕見疾病診斷市場：依技術分類

  • 介紹
  • 陣列技術
  • 次世代定序
  • 桑格序列

第8章罕見疾病診斷市場：依疾病類型

  • 介紹
  • 癌症
  • 心血管疾病
  • 皮膚科疾病
  • 內分泌/代謝疾病
  • 血液疾病
  • 免疫疾病
  • 肌肉骨骼疾病
  • 神經系統疾病

第9章 罕見疾病診斷市場：依最終用途分類

  • 介紹
  • 診斷實驗室
  • 醫院/診所
  • 研究機構和 CRO

第10章 南北美洲罕見疾病診斷藥物市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區罕見疾病診斷市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東、非洲罕見疾病診斷市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • 23andMe Inc.
  • 3billion, Inc.
  • Agilent Technologies Inc.
  • ARCHIMED Life Science GmbH
  • ARUP Laboratories
  • AstraZeneca PLC
  • Azenta Life Sciences
  • Baylor Genetics
  • Caris Life Sciences
  • CENTOGENE NV
  • Eurofins Scientific Inc.
  • F. Hoffmann-La Roche Ltd.
  • Fulgent Genetics, Inc.
  • Illumina, Inc.
  • In-Depth Genomics
  • Invitae Corporation
  • Laboratory Corporation of America Holdings
  • MedGenome Labs Ltd
  • OPKO Health, Inc.
  • PerkinElmer Inc.
  • Progenity, Inc.
  • Quest Diagnostics Incorporated
  • Sanofi SA
  • Thermo Fisher Scientific Inc.
  • Travere Therapeutics Inc.
Product Code: MRR-5C6F41F5B034

The Rare Disease Diagnostics Market was valued at USD 2.68 billion in 2023, expected to reach USD 3.12 billion in 2024, and is projected to grow at a CAGR of 17.36%, to USD 8.23 billion by 2030.

The market for rare disease diagnostics is characterized by its critical role in identifying and managing conditions that affect a small percentage of the population. This segment demands advanced technological innovation to improve the accuracy and timeliness of diagnostic processes. The necessity for enhanced diagnostics is underscored by the potential for early intervention and personalized treatment plans that can significantly improve patient outcomes. Applications span genetic testing, biomarker detection, and advanced imaging techniques, with end-use sectors including hospitals, diagnostic laboratories, and research institutions. Key factors driving growth in this market include increasing awareness about rare diseases, advancements in genomics and biotechnology, and supportive government policies and funding. Moreover, the shift towards personalized medicine plays a vital role, as does the integration of AI and machine learning to improve diagnostic accuracy and decision-making.

KEY MARKET STATISTICS
Base Year [2023] USD 2.68 billion
Estimated Year [2024] USD 3.12 billion
Forecast Year [2030] USD 8.23 billion
CAGR (%) 17.36%

Current opportunities lie in developing portable diagnostic tools and expanding the market in emerging economies where there is still significant unmet need. Strategic partnerships between biotech firms, government bodies, and healthcare providers can facilitate accelerated technology adoption. However, challenges persist, including high costs of advanced diagnostics, regulatory hurdles, and a scarcity of trained professionals. Market growth is also constrained by the heterogeneity and complexity of rare diseases, which complicates the development of standardized diagnostic protocols. Innovation prospects include enhancing genetic testing platforms, developing multi-omics approaches, and leveraging big data for deeper insights into disease mechanisms.

The market is inherently dynamic, fostering a competitive landscape where continuous research, agile adaptation to regulatory changes, and investment in talent development are imperative. Players in this sector must focus on collaborations across academia, tech, and healthcare industries to foster innovation and improve diagnostic accuracy. Overall, the rare disease diagnostics market holds significant potential for businesses willing to navigate its complexities while contributing to improved patient care.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Rare Disease Diagnostics Market

The Rare Disease Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of rare genetic diseases and the need for early & rapid diagnosis
    • Rising use in translational & genomic research for the identification of novel mutations
    • Government initiatives for diagnosis and treatment of rare diseases
  • Market Restraints
    • Stringent regulations associated with the approval process of new rare diseases genetic test
  • Market Opportunities
    • Advancements in genetic technology to Identify new rare disease genes
    • Favorable investments for diagnosis of rare genetic diseases
  • Market Challenges
    • Ethical concerns and access to limited information on rare disease

Porter's Five Forces: A Strategic Tool for Navigating the Rare Disease Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Rare Disease Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Rare Disease Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Rare Disease Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Rare Disease Diagnostics Market

A detailed market share analysis in the Rare Disease Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Rare Disease Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Rare Disease Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Rare Disease Diagnostics Market

A strategic analysis of the Rare Disease Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Rare Disease Diagnostics Market, highlighting leading vendors and their innovative profiles. These include 23andMe Inc., 3billion, Inc., Agilent Technologies Inc., ARCHIMED Life Science GmbH, ARUP Laboratories, AstraZeneca PLC, Azenta Life Sciences, Baylor Genetics, Caris Life Sciences, CENTOGENE N.V., Eurofins Scientific Inc., F. Hoffmann-La Roche Ltd., Fulgent Genetics, Inc., Illumina, Inc., In-Depth Genomics, Invitae Corporation, Laboratory Corporation of America Holdings, MedGenome Labs Ltd, OPKO Health, Inc., PerkinElmer Inc., Progenity, Inc., Quest Diagnostics Incorporated, Sanofi S.A., Thermo Fisher Scientific Inc., and Travere Therapeutics Inc..

Market Segmentation & Coverage

This research report categorizes the Rare Disease Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Component, market is studied across Consumable & Assay Kit and Diagnostic Instrument.
  • Based on Technology, market is studied across Array Technology, Next Generation Sequencing, and Sanger Sequencing.
  • Based on Disease Type, market is studied across Cancer, Cardiovascular Disorders, Dermatology Disease, Endocrine & Metabolism Diseases, Hematology Diseases, Immunological Disorders, Musculoskeletal Disorders, and Neurological Disorders.
  • Based on End-use, market is studied across Diagnostic Laboratories, Hospitals & Clinics, and Research Laboratories & CROs.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of rare genetic diseases and the need for early & rapid diagnosis
      • 5.1.1.2. Rising use in translational & genomic research for the identification of novel mutations
      • 5.1.1.3. Government initiatives for diagnosis and treatment of rare diseases
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent regulations associated with the approval process of new rare diseases genetic test
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in genetic technology to Identify new rare disease genes
      • 5.1.3.2. Favorable investments for diagnosis of rare genetic diseases
    • 5.1.4. Challenges
      • 5.1.4.1. Ethical concerns and access to limited information on rare disease
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Rare Disease Diagnostics Market, by Component

  • 6.1. Introduction
  • 6.2. Consumable & Assay Kit
  • 6.3. Diagnostic Instrument

7. Rare Disease Diagnostics Market, by Technology

  • 7.1. Introduction
  • 7.2. Array Technology
  • 7.3. Next Generation Sequencing
  • 7.4. Sanger Sequencing

8. Rare Disease Diagnostics Market, by Disease Type

  • 8.1. Introduction
  • 8.2. Cancer
  • 8.3. Cardiovascular Disorders
  • 8.4. Dermatology Disease
  • 8.5. Endocrine & Metabolism Diseases
  • 8.6. Hematology Diseases
  • 8.7. Immunological Disorders
  • 8.8. Musculoskeletal Disorders
  • 8.9. Neurological Disorders

9. Rare Disease Diagnostics Market, by End-use

  • 9.1. Introduction
  • 9.2. Diagnostic Laboratories
  • 9.3. Hospitals & Clinics
  • 9.4. Research Laboratories & CROs

10. Americas Rare Disease Diagnostics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Rare Disease Diagnostics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Rare Disease Diagnostics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. 23andMe Inc.
  • 2. 3billion, Inc.
  • 3. Agilent Technologies Inc.
  • 4. ARCHIMED Life Science GmbH
  • 5. ARUP Laboratories
  • 6. AstraZeneca PLC
  • 7. Azenta Life Sciences
  • 8. Baylor Genetics
  • 9. Caris Life Sciences
  • 10. CENTOGENE N.V.
  • 11. Eurofins Scientific Inc.
  • 12. F. Hoffmann-La Roche Ltd.
  • 13. Fulgent Genetics, Inc.
  • 14. Illumina, Inc.
  • 15. In-Depth Genomics
  • 16. Invitae Corporation
  • 17. Laboratory Corporation of America Holdings
  • 18. MedGenome Labs Ltd
  • 19. OPKO Health, Inc.
  • 20. PerkinElmer Inc.
  • 21. Progenity, Inc.
  • 22. Quest Diagnostics Incorporated
  • 23. Sanofi S.A.
  • 24. Thermo Fisher Scientific Inc.
  • 25. Travere Therapeutics Inc.

LIST OF FIGURES

  • FIGURE 1. RARE DISEASE DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. RARE DISEASE DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. RARE DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. RARE DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. RARE DISEASE DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. RARE DISEASE DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY CONSUMABLE & ASSAY KIT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC INSTRUMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY ARRAY TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DERMATOLOGY DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY ENDOCRINE & METABOLISM DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY HEMATOLOGY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES & CROS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 195. RARE DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 196. RARE DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023